Another monoclonal antibody, atezolizumab, that targets PD-L1 was evaluated in combination with the anti-VEGF antibody, bevacizumab, in a phase 1b trial involving 26 treatment-naïve patients with advanced HCC [61]. The gene discussed is CD274; the disease is hepatocellular carcinoma.